MARKET

INO

INO

Inovio Pharmaceu
NASDAQ
10.95
+0.12
+1.11%
After Hours: 11.30 +0.35 +3.20% 19:05 07/25 EDT
OPEN
10.92
PREV CLOSE
10.83
HIGH
11.46
LOW
10.86
VOLUME
301.40K
TURNOVER
0
52 WEEK HIGH
14.75
52 WEEK LOW
3.888
MARKET CAP
283.72M
P/E (TTM)
-1.9777
1D
5D
1M
3M
1Y
5Y
1D
Inovio Receives Advanced Therapy Medicinal Product Certificate From EMA For Quality And Non-Clinical Data For Lead Candidate INO-3107
Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Application. European Medicines Agency's Committee for Advanced Therapies has certified the quality and non-clinical data for INO-3107. INOVIO is a biotechnology company focused on developing and commercializing DNA medicines.
Benzinga · 1d ago
INOVIO RECEIVES ADVANCED THERAPY MEDICINAL PRODUCT CERTIFICATE FROM EUROPEAN MEDICINES AGENCY FOR QUALITY AND NON-CLINICAL DATA FOR LEAD CANDIDATE INO-3107
Reuters · 1d ago
Weekly Report: what happened at INO last week (0715-0719)?
Weekly Report · 4d ago
Analysts Conflicted on These Healthcare Names: Daiichi Sankyo Company (OtherDSKYF), Inovio Pharmaceuticals (INO) and Molina Healthcare (MOH)
TipRanks · 07/15 12:12
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target
Benzinga · 07/15 10:30
Weekly Report: what happened at INO last week (0708-0712)?
Weekly Report · 07/15 09:26
Undercovered Dozen: Evergy, Navitas Semiconductor, Whirlpool And More
Home Stock Ideas Quick Picks & Lists Undercovered Dozen: Evergy, Navitas Semiconductor, Whirlpool And More. This edition of the 'Undercovered' Dozen highlights twelve ideas from June 28th - July 11th on stocks with limited coverage. Newmont Corporation and Teck Resources are highlighted as a pair trade in the Industrials space. Evergy faces risks in the AI data center market, but could benefit from chip proliferation.
Seeking Alpha · 07/12 19:15
Inovio Pharmaceuticals Receives ‘Buy’ Rating Amidst UK Regulatory Advancements and Promising RRP Treatment Outlook
TipRanks · 07/11 16:55
More
About INO
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Webull offers Inovio Pharmaceuticals Inc stock information, including NASDAQ: INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.